Rani Therapeutics Holdings Inc

Rani Therapeutics secures a $1.085 billion Chugai partnership and $60.3 m funding, boosting its oral biologics platform and investor confidence.

Rani Therapeutics Holdings Inc has seen a significant surge in its market value, from $0.471 to over $18 million, following a $60.3 million private placement and a $1.09 billion licensing agreement with Chugai Pharmaceutical Co., positioning the com…

Rani Therapeutics Holdings Inc. has announced key developments, including a $3 million registered direct offering and a late-breaking presentation at ENDO 2025, showcasing its innovative oral biologics delivery system, RaniPill.

Rani Therapeutics Holdings Inc’s recent preclinical success with oral semaglutide delivery has sparked excitement, but its stock price volatility and complex valuation landscape raise concerns about the company’s financial stability.